Core Viewpoint - The company, Giant Medical Holdings (02393), anticipates a significant decline in its unaudited consolidated net profit for the six months ending June 30, 2025, projecting it to be no less than RMB 10 million, compared to approximately RMB 1.093 billion for the six months ending June 30, 2024 [1] Group 1 - The expected decline in net profit for the mid-2025 period is primarily attributed to the absence of a profit of approximately RMB 1.083 billion recognized in the mid-2024 period from the redemption of the company's originally scheduled 2026 due preference notes at a discount [1] - Additionally, the decrease in revenue from the medical products segment is also a contributing factor to the anticipated reduction in profit [1]

智通财经APP讯，映美控股(02028)公布，相比去年同期亏损人民币4349.5万元，该集团预期于2025年上 半年取得亏损人民币3500万元至4000万元。亏损的主要原因乃由于打印机需求下降和计提资产减值，以 及医疗产品尚未形成规模销售导致。 此外，公司已申请股份自2025年8月13日上午9点起复牌。 ...

Company Performance - SurModics reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of $0.21 per share, and improved from a loss of $0.27 per share a year ago, representing an earnings surprise of +128.57% [1] - The company posted revenues of $29.57 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.29%, although this is a decline from year-ago revenues of $30.34 million [2] - Over the last four quarters, SurModics has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Outlook - SurModics shares have declined approximately 11.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $29.98 million, and for the current fiscal year, it is -$0.57 on revenues of $116.33 million [7] - The estimate revisions trend for SurModics was unfavorable prior to the earnings release, resulting in a Zacks Rank 5 (Strong Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which SurModics belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - VAREX IMAGING reported quarterly earnings of $0.18 per share, significantly exceeding the Zacks Consensus Estimate of $0.04 per share, marking an earnings surprise of +350.00% [1][2] Financial Performance - The company achieved revenues of $203 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.73%, although this represents a decline from year-ago revenues of $209.1 million [2] - Over the last four quarters, VAREX IMAGING has consistently surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - VAREX IMAGING shares have declined approximately 51.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current Zacks Rank for VAREX IMAGING is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $199.03 million, while the estimate for the current fiscal year is $0.42 on revenues of $801.93 million [7] - The trend of estimate revisions for VAREX IMAGING was mixed prior to the earnings release, which may change following the recent results [6] Industry Context - The Medical - Products industry, to which VAREX IMAGING belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Financial Performance - BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $25.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.98%, although this is a decline from year-ago revenues of $28.33 million [2] - Over the last four quarters, BioLife Solutions has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance and Outlook - BioLife Solutions shares have declined approximately 18.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $24.55 million, and for the current fiscal year, it is $0.02 on revenues of $97.83 million [7] Industry Context - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Group 1 - Cresco Labs Inc. reported a quarterly loss of $0.05 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.16 per share a year ago, indicating a surprise of -25.00% [1] - The company posted revenues of $163.62 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.15%, and down from $184.36 million in the same quarter last year [2] - Cresco Labs Inc. shares have declined approximately 24.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Group 2 - The earnings outlook for Cresco Labs Inc. is uncertain, with current consensus EPS estimates at -$0.03 on revenues of $169.47 million for the upcoming quarter and -$0.11 on revenues of $675.98 million for the current fiscal year [7] - The Zacks Industry Rank places the Medical - Products sector in the bottom 37% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact stock performance [8] Group 3 - The estimate revisions trend for Cresco Labs Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $0.95 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.94%. A quarter ago, it was expected that this medicine distributor would post earnings of $1.3 per share when it actually produced earnings of $1.32, delivering a surprise of +1.54%.Over the last four ...

Core Viewpoint - Haemonetics reported quarterly earnings of $1.1 per share, exceeding the Zacks Consensus Estimate of $1.01 per share, and showing a slight increase from $1.02 per share a year ago [1][2]. Financial Performance - The earnings surprise for the quarter was +8.91%, with the company also surpassing earnings expectations in the previous quarter by +1.64% [2]. - Revenues for the quarter ended June 2025 were $321.39 million, which was 5.97% above the Zacks Consensus Estimate, although it represented a decline from $336.17 million in the same quarter last year [3]. Stock Performance - Haemonetics shares have declined approximately 3% since the beginning of the year, contrasting with a 7.9% gain in the S&P 500 [4]. - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [7]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.16, with projected revenues of $321.11 million, and for the current fiscal year, the EPS estimate is $4.89 on revenues of $1.3 billion [8]. - The outlook for the Medical - Products industry, where Haemonetics operates, is currently in the bottom 37% of Zacks industries, which may impact stock performance [9].

Core Viewpoint - Perrigo reported quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.59 per share, but showing an increase from $0.53 per share a year ago, indicating a -3.39% earnings surprise [1] - The company posted revenues of $1.06 billion for the quarter, missing the Zacks Consensus Estimate by 2.63%, and a slight decrease from $1.07 billion year-over-year [2] Financial Performance - Over the last four quarters, Perrigo has surpassed consensus EPS estimates two times [2] - The company has not been able to beat consensus revenue estimates over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $1.12 billion, and for the current fiscal year, it is $3.04 on revenues of $4.44 billion [7] Stock Performance and Outlook - Perrigo shares have increased by approximately 3.5% since the beginning of the year, compared to the S&P 500's gain of 7.1% [3] - The company's earnings outlook and management's commentary on the earnings call will be crucial for future stock price movements [3][4] - The estimate revisions trend for Perrigo was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Perrigo belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Cresco Labs Inc., is expected to report a quarterly loss of $0.04 per share, with revenues projected to decline by 11.1% year-over-year [9]

Financial Performance - Evolus, Inc. reported a quarterly loss of $0.24 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -166.67% [1] - The company posted revenues of $69.39 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 16.33%, compared to year-ago revenues of $66.91 million [2] - Over the last four quarters, Evolus has not surpassed consensus EPS or revenue estimates [2] Stock Performance - Evolus shares have declined approximately 17.5% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current Zacks Rank for Evolus is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $86.76 million, and -$0.11 on revenues of $350.01 million for the current fiscal year [7] - The outlook for the Medical - Products industry, to which Evolus belongs, is currently in the bottom 38% of over 250 Zacks industries, which may impact the stock's performance [8]